Michael Conick Hanley
Geschäftsführer bei ALTO NEUROSCIENCE, INC.
Vermögen: 50 608 $ am 31.05.2024
Aktive Positionen von Michael Conick Hanley
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| ALTO NEUROSCIENCE, INC. | Geschäftsführer | 20.05.2024 | - |
Karriereverlauf von Michael Conick Hanley
Ehemalige bekannte Positionen von Michael Conick Hanley
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| SPYRE THERAPEUTICS, INC. | Corporate Officer/Principal | 04.11.2019 | 14.04.2023 |
Esteve Pharmaceuticals S.A.
 Esteve Pharmaceuticals S.A. Pharmaceuticals: OtherHealth Technology Esteve Pharmaceuticals S.A. operates as a global pharmaceutical company. It provides Ophthalmology and other Pathologies therapies. The company is headquartered in Barcelona, Spain. | Corporate Officer/Principal | 01.04.2018 | 01.09.2019 |
| HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY | Vertrieb & Marketing | 01.07.2015 | 01.06.2017 |
Ausbildung von Michael Conick Hanley
| Kellogg School of Management | Masters Business Admin |
| Notre Dame University | Undergraduate Degree |
Statistik
International
| Vereinigte Staaten | 4 |
| Libanon | 2 |
| Spanien | 2 |
Operativ
| Corporate Officer/Principal | 2 |
| Masters Business Admin | 1 |
| Undergraduate Degree | 1 |
Sektoral
| Health Technology | 5 |
| Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| SPYRE THERAPEUTICS, INC. | Health Technology |
| ALTO NEUROSCIENCE, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Esteve Pharmaceuticals S.A.
Esteve Pharmaceuticals S.A. Pharmaceuticals: OtherHealth Technology Esteve Pharmaceuticals S.A. operates as a global pharmaceutical company. It provides Ophthalmology and other Pathologies therapies. The company is headquartered in Barcelona, Spain. | Health Technology |
Horizon Therapeutics Plc
 Horizon Therapeutics Plc Pharmaceuticals: MajorHealth Technology Horizon Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland. | Health Technology |
- Börse
- Insiders
- Michael Conick Hanley
- Erfahrung
